Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers March 22, 2022 Read More
Lung Therapeutics, Inc. Strengthens Board of Directors with Appointment of Biopharmaceutical Veteran William C. Fairey August 31, 2021 Read More
Lung Therapeutics Announces Appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development July 13, 2021 Read More
Lung Therapeutics Announces Appointment of Cory M. Hogaboam, Ph.D., as Chief Scientific Officer April 13, 2021 Read More
Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions November 12, 2020 Read More
Lung Therapeutics Receives SBIR Award for Kidney Fibrosis Research; Principal Investigator BreAnne Mackenzie Will Speak at 4th Annual IPF Summit 2020/Digital August 21, 2020 Read More
Lung Therapeutics, Inc. Raises $36 Million in Series C Financing to Advance Clinical Pipeline June 10, 2019 Read More
Lung Therapeutics, Inc. Announces New Chief Financial Officer and Board Member February 4, 2019 Read More
Lung Therapeutics, Inc. Raises $14.3 Million Series B Financing to Treat Unmet Needs in Lung Disease and Fibrosis June 6, 2017 Read More
Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of Lti-01 in Australia and New Zealand March 15, 2017 Read More
